Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer - Trial NCT06409429
Access comprehensive clinical trial information for NCT06409429 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 146 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2/3
May 01, 2024
May 30, 2027
Primary Outcome
relapse-free survival (RFS)
Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The
 main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab
 combined with GX for postoperative adjuvant treatment of pancreatic cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06409429
Non-Device Trial